The European Medicines Agency Review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the Treatment of Advanced Gastric Cancer When Given in Combination with Cisplatin: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use (CHMP)

The product Teysuno™ (S-1) contains tegafur, a prodrug of 5-fluorouracil (5-FU), and two modulators of 5-FU metabolism, gimeracil and oteracil. The main clinical study in this application was a randomized controlled study comparing S-1 plus cisplatin with 5-FU plus cisplatin. In this study, median o...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Matt, Petra, van Zwieten-Boot, Barbara, Calvo Rojas, Gonzalo, ter Hofstede, Hadewych, Garcia-Carbonero, Rocio, Camarero, Jorge, Abadie, Eric, Pignatti, Francesco
Format: Artigo
Idioma:Inglês
Publicat: AlphaMed Press 2011
Matèries:
Regulatory Issues: EMA
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228070/
https://ncbi.nlm.nih.gov/pubmed/21963999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0224
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars